GLG News by Oncologists in Private Practice in the U.S.

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

Avastin In Breast cancer

February 19, 2008

Analysis of:In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com

New data with low and high dose of Avastin with Taxoter

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

improve Overall survival in prostate cancer

February 19, 2008

Analysis of:Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). Data is very impressive. This may lead FDA approval in prostate cancer in next 3-6 months.

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

Avastin in breast cancer

December 7, 2007

Analysis of:F.D.A. Criticizes Avastin Use for Breast Cancer | www.nytimes.com

“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never used Avastin to treat breast cancer, but he knows other doctors do, despite the lack of FDA’s blessing. “Physicians always want to do something for the patient,” he said. But he believes the panel’s vote “will make them think twice” before they try Avastin for breast cancer. “This drug is a good drug,” Buzdar added. “It does work in a number of other cancers where it not only prolongs control of the disease but it keeps more patients alive. In breast cancer, it has not panned out.”

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

CMS

August 29, 2007

Analysis of:New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors | www.medicalnewstoday.com

CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

ERBITUX

August 9, 2007

Analysis of:Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program | www.pipelinereview.com

The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

ERBITUX

August 9, 2007

Analysis of:Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program | www.pipelinereview.com

The coverage restrictions placed on the FDA-approved indication have no scientific basis and are incompatible with good clinical practice," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Global Research and Development at Amgen. "We are concerned that inappropriately limiting coverage for ESAs at hemoglobin levels less than 10 g/dL will both increase blood transfusions and severely compromise the high quality of cancer care delivered by American physicians. In our view, restricting coverage in this way is unreasonable, impractical and unworkable. Moreover, through this coverage decision, the CMS has undermined the ability of physicians to decide how best to administer ESA therapy to their patients through carefully defined dosing guidance articulated by the FDA."

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

ESA

August 6, 2007

Analysis of:Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology | www.pipelinereview.com

My understading id medicare need to cover all FDA indicated drugs. Here CMS violating FDA indication for Aranesp and procrit

Taral PatelOncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

Growth factor use

August 3, 2007

Analysis of:Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology | www.pipelinereview.com

Decrease use by 20-25% use of ESA. This may lead discounting and higher rebate from both amgen and orto-biotech to sustain market share. Since most of amgen contract with aranesp and neulasta use. It may effect use of neulasta. Next 6 month CMS may restrict use of Neulasta and neupogen for neutropenia associated with chemotherapy.

Page : 11 to 8 of 8